The proposed channel-enzyme Transient Receptor Potential Melastatin 2 does not possess ADP ribose hydrolase activity

Abstract

Transient Receptor Potential Melastatin 2 (TRPM2) is a Ca2+-permeable cation channel essential for immunocyte activation, insulin secretion, and postischemic cell death. TRPM2 is activated by ADP ribose (ADPR) binding to its C-terminal cytosolic NUDT9-homology (NUDT9H) domain, homologous to the soluble mitochondrial ADPR pyrophosphatase (ADPRase) NUDT9. Reported ADPR hydrolysis classified TRPM2 as a channel-enzyme, but insolubility of isolated NUDT9H hampered further investigations. Here we developed a soluble NUDT9H model using chimeric proteins built from complementary polypeptide fragments of NUDT9H and NUDT9. When expressed in E.coli, chimeras containing up to ~90% NUDT9H sequence remained soluble and were affinity-purified. In ADPRase assays the conserved Nudix-box sequence of NUDT9 proved essential for activity (kcat~4-9s-1), that of NUDT9H did not support catalysis. Replacing NUDT9H in full-length TRPM2 with soluble chimeras retained ADPR-dependent channel gating (K1/2~1-5μM), confirming functionality of chimeric domains. Thus, TRPM2 is not a 'chanzyme'. Chimeras provide convenient soluble NUDT9H models for structural/biochemical studies.

Article and author information

Author details

  1. Iordan Iordanov

    Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8251-5857
  2. Csaba Mihályi

    Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7536-3066
  3. Balázs Tóth

    Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
  4. László Csanády

    Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary
    For correspondence
    csanady.laszlo@med.semmelweis-univ.hu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6547-5889

Reviewing Editor

  1. David E Clapham, Howard Hughes Medical Institute, Boston Children's Hospital, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of Semmelweis University (22.1/1935/3/2011).

Version history

  1. Received: May 6, 2016
  2. Accepted: July 5, 2016
  3. Accepted Manuscript published: July 6, 2016 (version 1)
  4. Version of Record published: August 4, 2016 (version 2)

Copyright

© 2016, Iordanov et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,322
    views
  • 250
    downloads
  • 49
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Iordan Iordanov
  2. Csaba Mihályi
  3. Balázs Tóth
  4. László Csanády
(2016)
The proposed channel-enzyme Transient Receptor Potential Melastatin 2 does not possess ADP ribose hydrolase activity
eLife 5:e17600.
https://doi.org/10.7554/eLife.17600

Share this article

https://doi.org/10.7554/eLife.17600